Prostate cancer Pill-Taking habits under the microscope

NCT ID NCT07451002

Recruiting now Knowledge-focused Sponsor: Janssen Cilag S.A.S. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn what factors affect real-world medication use, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide
What this could lead to: If successful, this could help doctors understand which patients are likely to skip doses and why, leading to better support and possibly improved treatment outcomes.
What could go wrong: This is an observational study, not a treatment trial, so it won't test if apalutamide works better or worse. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

Centre Francois Baclesse
RECRUITING

Caen, 14076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.